奈达铂或顺铂联合多西他赛治疗晚期非小细胞肺癌

Efficacy of docetasel combined with nedaplatin or cisplatin in patients with advanced non-small cell lung cancer

目的:对比分析奈达铂联合多西他赛化疗方案和顺铂联合多西他赛化疗方案治疗中晚期非小细胞肺癌的疗效和不良反应。方法:73例中晚期非小细胞肺癌患者,其中37例采用奈达铂联合多西他赛治疗(试验组),36例采用顺铂联合多西他赛治疗(对照组)。结果:试验组有效率为32.43%,和对照组(36.11%)相比,无统计学差异(P>0.05);试验组胃肠道反应发生率明显低于对照组(P<0.01);两组肾脏毒性无明显差异(P>0.05);两组白细胞下降发生率分别为24.32%和25.00%(P>0.05);试验组血小板下降较对照组显著(48.65%vs27.78%,P<0.05)。结论:奈达铂联合多西他赛治疗中晚期非小细胞肺癌疗效不低于顺铂联合多西他赛,但胃肠道毒性显著减轻。

Objective：To determine the efficacy and side effects of the regimens for combined chemotherapy （docetaxel combined with nedaplatin or cisplatin） in patients with advanced non-small cell lung cancer.Methods：A total of 73 patients with advanced non-small cell lung cancer were divided into two groups,and treated with docetaxel ＋ nedaplatin （test,n=37） or docetaxel ＋ cisplatin （control,n=36）.Results：The response rate was 32.43% in test group and 36.11% in control group;there was no significant difference between two groups （P〉0.05）.The rate of digestive reactions was significantly lower in test group than in control group （P〈0.01）.The incidence of leukopenia （24.32% vs 25.00%） and nephrotoxicity were not significantly different in two groups.Thrombocytopenia rate was higher in test group （48.65%） that in control group （27.78%,P〈0.05）.Conclusion：The regimen of nedaplatin combined with docetaxel shows a similar efficacy but a lower digestive reactions as compared with that of cisplatin combined with docetaxel.